---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-22-029065"
form_type: "8-K"
ticker: "VCEL"
cik: "0000887359"
company_name: "Vericel Corp"
filed_at: "2022-11-09T23:59:59+00:00"
generated_at: "2026-06-22T02:29:42.981686+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Vericel Q3 revenue $38.6M (+12% YoY); MACI $31M (+30%); net loss $6.6M; FY22 guidance $164-166M

## Summary
- Total net revenue $38.6M (+12% YoY); MACI net revenue $31.0M (+30% YoY); Epicel $7.3M; NexoBrid $0.2M.
- Net loss of $6.6M ($0.14 per share) vs $4.9M loss in Q3 2021; adjusted EBITDA $3.3M.
- Full-year 2022 guidance: total revenue $164-166M, MACI $130-132M, burn care ~$34M, gross margin mid-60%.
- Cash and investments $133M, no debt; ninth straight quarter of positive adjusted EBITDA and operating cash flow.
- NexoBrid BLA review progressing with FDA inspections; Type C meeting scheduled for MACI arthroscopic delivery.

## SEC filing metadata
- accession: 0001628280-22-029065
- form_type: 8-K
- ticker: VCEL
- cik: 0000887359
- company_name: Vericel Corp
- filed_at: 2022-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/887359/000162828022029065/0001628280-22-029065-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/887359/000162828022029065/vcel-20221109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-22-029065
- JSON: https://secwatch.observer/filing/0001628280-22-029065.json
- Plain text: https://secwatch.observer/filing/0001628280-22-029065.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.